Question 1

What are the potential side effects of gevokizumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options I have?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

Question 3

What should I expect during the study in terms of visits and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any specific risks I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience a side effect during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum clinical trial (NCT02318914). Contact the study team or your healthcare provider for specific answers.

What this study is about